|
EP3026122A1
|
|
Cellular-based method for determining the potency of defibrotide
|
|
US2014363394A1
|
|
Formulation having mobilizing activity
|
|
CA2874960A1
|
|
Euglobulin-based method for determining the biological activity of defibrotide
|
|
WO2012063272A1
|
|
Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
|
|
EP2103689A1
|
|
Synthetic phosphodiester oligonucleotides and therapeutical uses thereof
|
|
AU2007231651A1
|
|
Defibrotide and/or oligodeoxyribonucleotides for treating angiogenesis-dependent tumors
|
|
EP1982722A1
|
|
Use of oligotide for the treatment of renal diseases
|
|
EP1872787A1
|
|
Use of defibrotide for the inhibition of heparanase
|
|
KR20070120953A
|
|
Formulation with anti-tumor action
|
|
BRPI0607833A2
|
|
use of defibrotide and / or oligodeoxyribonucleotides
|
|
CN1972705A
|
|
Use of sulglicotide for the treatement of mucositis
|
|
CN1845746A
|
|
Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents
|
|
EP1493810A1
|
|
DNA-based aptamers for human cathepsin G
|
|
EP1325962A1
|
|
A method for determining the biological activity of defibrotide
|
|
YU79802A
|
|
Formulation having mobilizing activity
|
|
AU3501099A
|
|
Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
|
|
IL130405D0
|
|
Use of complexes between cationic liposomes and polydeoxyribonucleotides for preparation of medicaments
|
|
EP1059092A1
|
|
Use of complexes among cationic liposomes and polydeoxyribonucleotides as medicaments
|
